SATURDAY 9 OCTOBER 2021
Plenary Session 2 The great wall of Fungi
Chairs: Carol Munro, United Kingdom & Julian Naglik, United Kingdom
08:30
PS2.1 Immune recognition of fungi: the writing on the wall
Neil Gow, United Kingdom, FECMM
09:00
PS2.2 Aspergillus fumigatus cell wall
Isabel Valsecchi, France
09:30
Top 10 Papers: Clinical / diagnostics / treatment
Don Sheppard, Canada, FECMM & Katrien Lagrou, Belgium, FECMM
09:45
Top 10 Papers: Basic / immunology / genomics
Julian Naglik, United Kingdom & Agostinho Carvalho, Portugal, FECMM
10:00
Coffee break
Quiz the expert sessions
10:15
Q01 PCR based diagnosis of invasive mold infection
Maurizio Sanguinetti, Italy & Sean Zhang , USA
10:15
Q02 Recurrent Vulvovaginal Candidiasis (RVVC) - A diagnostic challenge
Riina Richardson, United Kingdom, FECMM & David Perlin, USA
10:15
Q03 Clinical Mycology- How to get things going in LMICs
Rita Oladele, Nigeria, FECMM & Bright Ocansey, Ghana
10:15
Q04 Management of candida in the ICU
Luis Ostrosky-Zeichner, USA, FECMM & Patricia Muñoz, Spain
10:15
Q05 Beta d glucan in paediatrics
Laura Ferreras-Antolin, United Kingdom & Thomas Lehrnbecher, Germany
10:15
Q06 Teaching Medical Mycology
Ester Segal, Israel, FECMM & June Kwon-Chung, USA
11:00
Poster session
12:00
Lunch break
12:30
Sponsored Integrated Symposium 2
More information on https://www.timm2021.org/sponsored-symposia/
14:15
Parallel Symposia 5-9
Symposium 5 Dermatophytes and fungal skin infections
Chairs: Sevtap Arikan Akdagli, Turkey, FECMM & Fanny Lanternier, France, FECMM
14:15
S05.1 Global epidemiology: What is changing, what is remarkable?
Rudramurthy Shivaprakash, India, FECMM
14:35
S05.2 How to determine MICs for my dermatophyte strain: Protocoles, tips, and trics
Sevtap Arikan Akdagli, Turkey, FECMM
14:55
S05.3 Primary immunodeficiencies and dermatophytoses: What else do we know?
Fanny Lanternier, France, FECMM
15:15
S05.4 Malassezia: epidemiology and host-response studies’
Dora Corzo-Leon, Scotland, United Kingdom
15:35
S05.5 Evaluation of the multiplex real-time PCR DermaGenius® assay for the detection of dermatophytes in hair samples from Senegal
Mouhamadou Ndiaye, Senegal
Symposium 6 Immunity to fungi
Chairs: Agostinho Carvalho, Portugal, FECMM & Rebecca Drummond, United Kingdom
14:15
S06.1 How do Antibiotics Promote Susceptibility to Healthcare-Associated Fungal Infections?
Rebecca Drummond, United Kingdom
14:35
S06.2 Human genetic determinism of fungal diseases
Anna Puel, France
14:55
S06.3 Immunity to fungi in pneumocystis
Jay K Kolls, USA
15:15
S06.4 Serum proteins, crucial factors for human physiology that are exploited by Candida species to promote pathogenicity
Mark Gresnigt, Germany
15:30
S06.5 Increased efficacy of IL-18/posaconazole combination in a neutropenic animal model of pulmonary invasive aspergillosis by an azole resistant A.fumigatus isolate
Joseph Meletiadis, Greece
Symposium 7 Prophylaxis of Invasive Fungal Infections in Solid Organ Transplant Recipients
Chairs: Shahid Husain, Canada, FECMM & Cornelia Geisler Crone, Denmark
14:15
S07.1 Alternatives to drug treatment
Mihai Netea, the Netherlands
14:35
S07.2 Antifungal prophylaxis: Who, with what and how long?
Shmuel Shoham, USA
14:55
S07.3 Epidemiology
Shahid Husain, Canada, FECMM
15:15
S07.4 Side-effects and completion rates of universal versus targeted antifungal prophylaxis among lung transplant recipients 2010-2019
Cornelia Geisler Crone, Denmark
15:30
S07.5 Risk factors for and outcomes of invasive aspergillosis following kidney transplantation in the United States
Daniel Friedman, USA
Symposium 8 Update on diagnosis and treatment of chronic pulmonary aspergillosis (CPA)
Chairs: Aleksandra Barac, Serbia, FECMM & David Denning, United Kingdom, FECMM
14:15
S08.1 Diagnostic Value of Galactomannan in Bronchoalveolar Lavage Fluid for Chronic Respiratory Disease with Pulmonary Aspergillosis
Aleksandra Barac, Serbia, FECMM
14:35
S08.2 Underlying Conditions and Clinical Spectrum of Chronic Pulmonary Aspergillosis (CPA)
Eva Van Braeckel, Belgium
14:55
S08.3 Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis
Felix Bongomin, Uganda, FECMM
15:15
S08.4 Prevalence of chronic pulmonary aspergillosis among active pulmonary tuberculosis patients with persisting symptoms in Uganda
Martha Namusobya, Uganda
15:30
S08.5 CPAepi: a study to investigate epidemiological characteristics of Aspergillus spp. isolated from CPA patients
Juan Carlos Soto Debran, Spain
Symposium 9 Latest results of ECMM and international registries
Chairs: Tamas Papp, Hungary, FECMM & Danila Seidel, Germany, FECMM
14:15
S09.1 Distribution and Antifungal Susceptibility of yeasts causing invasive fungal diseases in China: An Update From the CHIF-NET Study
Yao Wang, China
14:30
S09.2 A global team effort - FungiScope
Danila Seidel, Germany, FECMM
14:45
S09.3 FUNGINOS – The Fungal Infection Network of Switzerland
Nina Khanna, Switzerland
15:00
S09.4 Update from ECMM and international registries: FungiScope Candida / CandiReg
Philipp Köhler, Germany, FECMM
15:15
S09.5 Epidemiology of Candida glabrata resistance in France and Germany within the frame of the ARest consortium
Alexandre Alanio, France, FECMM
15:30
S09.6 CPAnet: an International Chronic Pulmonary Aspergillosis Registry
Eva Van Braeckel, Belgium
15:45
Coffee break
16:15
Parallel Symposia 10-13
Symposium 10 Candida and other yeast infections
Chairs: Malcolm Richardson, United Kingdom, FECMM & Cornelia Lass-Flörl, Austria, FECMM
16:15
S10.1 Diagnosis of Candida: Culture, Beta-glucan and Mannan
Liz Johnson, United Kingdom, FECMM
16:35
S10.2 The role of PCR and T2 MR
Cornelia Lass-Flörl, Austria, FECMM
16:55
S10.3 Mixed Yeast infections - Common or not?
Ana Alastruey-Izquierdo, Spain, FECMM
17:15
S10.4 Epidemiology and Clinical Burden of Candida infections across Europe - Results of ECMM Candida III
Martin Hoenigl, Austria, FECMM & Maiken Arendrup, Denmark
Symposium 11 The Myc(icr)obiome and Fungal Infections
Chairs: Paul Bowyer, United Kingdom & Ilse Jacobsen, Germany
16:15
S11.1 The Lung mycobiom in health and disease
Paul Bowyer, United Kingdom
16:35
S11.2. Epidemiology of Fungal Infection in the ICU: Viral Infection a relevant risk factor?
Matteo Bassetti, Italy
16:55
S11.3 Mycobiome and invasive candidiasis
Tobias Hohl, USA, FECMM
17:15
S11.4 Mycobiome and microbial interactions
Ilse Jacobsen, Germany
17:25
S11.5 Development of a novel mycobiome diagnostic for fungal infection
Danielle Weaver, United Kingdom
17:35
S11.6 Effect of exposition to broad-spectrum antibiotics on the gut mycobiota of healthy volunteers
Margot Delavy, France
Symposium 12 Viral infections and fungal disease
Chairs: Monica Slavin, Australia & Juergen Prattes, Austria
16:15
S12.1 Immunology
Frank van de Veerdonk, the Netherlands
16:35
S12.2 Definition, Diagnosis and Treatment of COVID-19 associated pulmonary aspergillosis - ECMM/ISHAM Consensus Guidance
Philipp Köhler, Germany, FECMM
16:55
S12.3 Covid associated mucormycosis'
Arunaloke Chakrabarti, India, FECMM
17:10
S12.4 Cytomegalovirus infection and invasive fungal disease
Monica Slavin, Australia
17:25
S12.5 ECMM CAPA Pulmonary aspergillosis in critically ill coronavirus disease 2019 patients– a multinational study
Juergen Prattes, Austria
17:35
S12.6 Immunological profiles of patients with influenza-associated pulmonary aspergillosis (IAPA)
Intan Dewi, the Netherlands
Symposium 13 Emerging issues in mycology
Chair: Anuradha Chowdhary, India, FECMM & Matthew Fisher, United Kingdom
16:15
S13.1 Emergomyces
Nelesh Govender, South Africa, FECMM
16:35
S13.2 Emerging rare yeasts in outbreaks
Anuradha Chowdhary, India, FECMM
16:55
S13.3 Tracing patterns of evolution and acquisition of drug resistant Aspergillus fumigatus infection from the environment using population genomics
Matthew Fisher, United Kingdom
17:05
S13.4 EHA Guideline on antifungal prophylaxis in adult acute myeloid leukemia treated with novel agents
Jannik Stemler, Germany
17:15
S13.5 Candida auris clinical isolates from patients with COVID-19 in Saint Petersburg, Russia : identification, antifungal susceptibility
Ellina Oganesyan, Russia
17:25
S13.6 Hyperendemic zoonotic sporotrichosis: Implementation of a public health assistance service for human sporotrichosis in southern Brazil
Melissa Orzechowski Xavier, Brazil
18:00
Sponsored Integrated Symposium 3
More information on www.timm2021.org/sponsored-symposia
19:30
Sponsored reception